Compugen to Present UnigenX Platform at the 18th Annual PEGS Europe Summit

HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced an oral presentation at the 18^th Annual Protein and Antibody Engineering Summit (PEGS) Europe, taking place November 16-19, 2026, in Lisbon, Portugal.

The presentation will showcase UnigenX™, an expansion of the Company's computational discovery platform into targeted immune activation modalities, such as T cell engagers, designed to discover novel tumor-associated antigen targets and combinations for selective targeting of tumor cells. 

Title: UnigenX™: AI-Powered Discovery Platform for Novel Tumor-Associated Antigens for Targeted Immune Activation

Track: Advancing Multispecific Antibodies and Combination Therapy to the Clinic

Speaker: Dr. Roy Granit, Head of Computational Discovery at Compugen

Date & Time: Wednesday, November 18, 2026 at 18:30 GMT

Link: PEGS Europe 2026

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum-sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Lindsey Trickett 

Email: LindseyT@cgen.com 

Tel: +1 415 373 0892

SOURCE Compugen Ltd.